NCT06600425View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

June 6, 2025

Study Completion Date

August 27, 2025

Conditions
Primary Ciliary Dyskinesia
Interventions
DRUG

RCT1100

RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer

Trial Locations (2)

SW3 6NP

Royal Brompton Hospital, London

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors
All Listed Sponsors
lead

ReCode Therapeutics

INDUSTRY

NCT06600425 - A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD | Biotech Hunter | Biotech Hunter